Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818216 · ClinicalTrials.gov registry record · Phase 2
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
A Phase 2 study of Acute Kidney Injury and SARS CoV 2 Infection, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT04818216: Completed Phase 2 study of Acute Kidney Injury and SARS CoV 2 Infection, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04818216 is a Phase 2 study of Acute Kidney Injury and SARS CoV 2 Infection that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 28 participants, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04818216, a Phase 2 study of Acute Kidney Injury and SARS CoV 2 Infection, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.
Primary Outcome
Measure of NAD+ level in whole blood from treatment beginning to end
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nicotinamide riboside
Study Locations (4)
Texas
- The University of Texas Health Science Center at San Antonio - San Antonio
- University Health Systems - San Antonio
New York
- Icahn School of Medicine at Mount Sinai - New York
Washington
- Harborview Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2022-01-03 |
| Phase | Phase 2 |
What the finished NCT04818216 record still lists
NCT04818216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04818216 reports a single indexed study location in Texas, New York, Washington.
Frequently Asked Questions
What is clinical trial NCT04818216 about?
NCT04818216 is a clinical study titled "Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection". An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.
What is the current status of trial NCT04818216?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-06-11. Estimated completion is 2022-01-03.
What conditions does trial NCT04818216 study?
This clinical trial studies the following conditions: Acute Kidney Injury, SARS CoV 2 Infection.
What interventions are being tested in trial NCT04818216?
The interventions under investigation include: Placebo (DRUG), Nicotinamide riboside (DRUG).
Who is sponsoring clinical trial NCT04818216?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04818216 being conducted?
This trial has 4 study locations across New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04818216's enrollment target sits among peer trials
28 67th of 74 higher than 8 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI